Protein signature of lung cancer tissues

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Mehan, Michael R ^a   Ayers, Deborah ^a   Thirstrup, Derek ^b   Xiong, Wei ^b   Ostroff, Rachel M ^a   Brody, Edward N ^a   Walker, Jeffrey J ^a   Gold, Larry ^a,c   Jarvis, Thale C ^a   Janjic, Nebojsa ^a   Baird, Geoffrey S ^b   Wilcox, Sheri K ^a  

^a SomaLogic Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; TUMOR MARKER; PROTEOME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; TISSUE LEVEL; TISSUE SECTION; APOPTOSIS; BLOOD; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY);

AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859611365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035157     Document Type: Article

References (71)

1. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, et al. (2005) Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 129: 87-93.
2. Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, et al. (2009) Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 138: 412-418.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA- Cancer J Clin 58: 71-96.
4. Boyle P, Levin B, eds. (2008) World Cancer Report Lyon International Agency for Research on Cancer (IARC).
5. Gold L, Ayers D, Bertino J, Bock C, Bock A, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5: e15004.
6. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, et al. (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
7. Simpson-Haidaris PJ, Rybarczyk B, (2001) Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci 936: 406-425.
8. Diamandis EP, (2010) Cancer biomarkers: can we turn recent failures into success? J Natl Canc I 102: 1462-1467.
9. Ioannidis JPA, Panagiotou OA, (2011) Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305: 2200-2210.
10. Bossuyt PMM, (2011) The Thin Line Between Hope and Hype in Biomarker Research. JAMA 305: 2229-2230.
11. Hanahan D, Weinberg RA, (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
12. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, et al. (1998) Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiov Sur 115: 1007-1014.
13. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, et al. (2004) Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 10: 5361-5366.
14. Ohta Y, Waseda R, Minato H, Endo N, Shimizu Y, et al. (2006) Surgical results in T2N0M0 nonsmall cell lung cancer patients with large tumors 5 cm or greater in diameter: what regulates outcome? Ann Thorac Surg 82: 1180-1184.
15. Fontanini G, Boldrini L, Chinè S, Pisaturo F, Basolo F, et al. (1999) Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Brit J Cancer 79: 363-369.
16. Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, et al. (1999) Thrombospondins I and II Messenger RNA Expression in Lung Carcinoma: Relationship with p53 Alterations, Angiogenic Growth Factors, and Vascular Density. Clin Cancer Res pp. 155-161.
17. Senger DR, Galli SJ, Dvorak aM, Perruzzi Ca, Harvey VS, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
18. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z, (2000) Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 19: 557-568.
19. Oshika Y, Masuda K, Tokunaga T, Hatanaka H, Kamiya T, et al. (1998) Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4: 1785-1788.
20. Chen ZJ, Le HB, Zhang YK, Qian LY, Li WD, (2009) Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J Int Med Res 37: 551-556.
21. Jing R, Cui M, Wang J, Wang H, (2010) Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 57: 55-61.
22. Migita T, Narita T, Asaka R, Miyagi E, Nagano H, et al. (2010) Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol 176: 1756-1766.
23. Yfanti C, Mengele K, Gkazepis A, Weirich G, Giersig C, et al. (2008) Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues. Int J Mol Med 22: 421.
24. Cheng Y-J, Lee C-H, Lin Y-P, Huang J-Y, Su C-C, et al. (2008) Caspase-3 enhances lung metastasis and cell migration in a protease-independent mechanism through the ERK pathway. Int J Cancer 123: 1278-1285.
25. Bartling B, Hofmann H-S, Weigle B, Silber R-E, Simm A, (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301.
26. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, et al. (2010) Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiov Sur 139: 984-990.
27. Hofmann H-S, Hansen G, Richter G, Taege C, Simm A, et al. (2005) Matrix Metalloproteinase-12 Expression Correlates with Local Recurrence and Metastatic Disease in Non - Small Cell Lung Cancer Patients. Clin Cancer Res 11: 1086-1092.
28. Gupta S, Thirstrup D, Jarvis TC, Schneider DJ, Wilcox SK, et al. (2011) Rapid histochemistry using slow off-rate modified aptamers with anionic competition. AppI Immunohist M M 19: 273-278.
29. Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos Ea, et al. (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173: 879-891.
30. Allavena P, Chieppa M, Monti P, Piemonti L, (2004) From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immunol 24: 179-192.
31. The National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
32. Boeri M, Verri C, Conte D, Roz L, Modena P, et al. (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Nat Acad Sci USA 108: 3713-3718.
33. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, et al. (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20: 289-299.
34. Herbst RS, Heymach JV, Lippman SM, (2008) Molecular origins of cancer: lung cancer. N Engl J Med 359: 1367-1380.
35. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, et al. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22: 2616-2624.
36. Storey JD, (2002) A direct approach to false discovery rates. J Roy Stat Soc B 64: 479-498.
37. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, et al. (2006) CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7: R100.
38. Jones TR, Carpenter AE, Lamprecht MR, Moffat J, Silver SJ, et al. (2009) Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Nat Acad Sci USA 106: 1826-1831.
39. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, et al. (2009) Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia 11: 388-396.
40. Moran CJ, Arenberg DA, Huang C-C, Giordano TJ, Thomas DG, et al. (2002) RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 8: 3803-3812.
41. Takada M, Tada M, Tamoto E, Kawakami A, Murakawa K, et al. (2004) Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. J Surg Res 122: 61-69.
42. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, et al. (2004) Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Modern Pathol 17: 430-439.
43. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698.
44. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20: 2417-2428.
45. Lee Y-C, Wu C-T, Chen C-S, Hsu H-H, Chang Y-L, (2002) The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiov Sur 123: 502-507.
46. Zhang Z, Ma J, Li N, Sun N, Wang C, (2006) Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg 82: 243-248.
47. Yoo J, Kim CH, Song SH, Shim BY, Jeong YJ, et al. (2004) Expression of caspase-3 and c-myc in non-small cell lung cancer. Cancer Res Treat 36: 303-307.
48. Singhal S, Miller D, Ramalingam S, Sun S-Y, (2008) Gene expression profiling of non-small cell lung cancer. Lung Cancer 60: 313-324.
49. Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, et al. (2008) Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer 60: 277-284.
50. Chung-man Ho J, Zheng S, Comhair SA, Farver C, Erzurum SC, (2001) Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res 61: 8578-8585.
51. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, et al. (2005) Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167: 1763-1775.
52. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, et al. (2003) cDNA microarray analysis of gene expression in pathologic Stage IA nonsmall cell lung carcinomas. Cancer 97: 2798-2805.
53. Chang H, Iizasa T, Shibuya K, Iyoda A, Suzuki M, et al. (2004) Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. Cancer 100: 1665-1672.
54. Cangara HM, Ishida T, Hara T, Sun L, Toh R, et al. (2010) Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis. Microvascular research 80: 133-141.
55. Olchovsky D, Shimon I, Goldberg I, Shulimzon T, Lubetsky A, et al. (2002) Elevated insulin-like growth factor-1 and insulin-like growth factor binding protein-2 in malignant pleural effusion. Acta Oncol 41: 182-187.
56. Wegmann BR, Schöneberger HJ, Kiefer PE, Jaques G, Brandscheid D, et al. (1993) Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. Eur J Can 29A: 1578-1584.
57. Liu Y, Sun W, Zhang K, Zheng H, Ma Y, et al. (2007) Identification of genes differentially expressed in human primary lung squamous cell carcinoma. Lung Cancer 56: 307-317.
58. Chen Y, Cui T, Knösel T, Yang L, Zöller K, et al. (2011) IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer 73: 38-44.
59. Chen Y, Pacyna-Gengelbach M, Ye F, Knösel T, Lund P, et al. (2007) Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 211: 431-438.
60. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, et al. (2000) Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Resp Crit Care 162: 1957-1963.
61. Su J, Dong Q, Huang J, Bao G, (2004) Quantitative detection of interleukin 8 gene expression in lung cancer by real-time polymerase chain reaction. Chin J Clin Oncol 1: 126-130.
62. Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, et al. (2007) Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58: 384-391.
63. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, et al. (2009) Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29: 2513-2517.
64. Hofmann H-S, Bartling B, Simm A, Murray R, Aziz N, et al. (2006) Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. Oncol Rep 16: 587-595.
65. Schraml P, Bendik I, Ludwig CU, (1997) Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res 57: 3669-3671.
66. Chijiwa T, Abe Y, Inoue Y, Matsumoto H, Kawai K, et al. (2009) Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. Oncol Rep 22: 279-283.
67. Carlini MJ, Dalurzo MCL, Lastiri JM, Smith DE, Vasallo BC, et al. (2010) Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 41: 697-705.
68. Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C, et al. (1999) Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 5: 2094-2102.
69. Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, et al. (2000) The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 11: 327-332.
70. Kim T-M, Yim S-H, Lee J-S, Kwon M-S, Ryu J-W, et al. (2005) Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res 11: 8235-8242.
71. Son JW, Kim YJ, Cho HM, Lee SY, Jang JS, et al. (2009) MicroRNA Expression Profiles in Korean Non-Small Cell Lung Cancer. Tuberc Respir Dis 67: 413.